Radionuclide therapy for bone metastases by drugs based on Re-188
Vol. 62 No. 4 (2016), Articles
Vol. 62 No. 4 (2016)

Radionuclide therapy for bone metastases by drugs based on Re-188

Articles
https://doi.org/10.37469/0507-3758-2016-62-4-401-409
Published 15.12.2016
Clinic of Nuclear Medicine, Frankfurt am Oder
A. F. Tsyb Medical Radiological Research Center -branch of the National Medical Research Radiological Center
A. F. Tsyb Medical Radiological Research Center -branch of the National Medical Research Radiological Center

Abstract

The systemic radionuclide therapy with bone affinity substances is an effective therapy in bone palliative treatment. Studies with radiolabeled Bisphosphonate or strontium-89 show reduction of pain in 70-80% and about 20% of treated patients are pain-free. The generator product rhenium-188 represents an interesting radionuclide for bone pain palliation. It is readily available and with appropriate patient numbers is very cost-effective. Radiopharmaceuticals with Re-188 show a comparable effectiveness in bone pain palliation and bone marrow toxicity as the other known radioactive Bisphosphonate. Repeat courses of treatment with rhenium-188 HEDP even a slightly increased survival could be observed. Using therapy with alpha emitters Radium-223 in prostate cancer patients with bone metastases there was observed a prolongation of survival by 3,6 months compared with placebo. Two drugs are created in Russia on the basis of Re-188. Phosphoren is an analog of Re-188-HEDP. It showed properties similar to them in clinical studies. Complex Re-188-zoledronic acid (Zoleren) is a unique development that combines the therapeutic effect of zoledronic acid and Re-188.
https://doi.org/10.37469/0507-3758-2016-62-4-401-409
PDF (Русский)

References

Кочетова Т. Ю., Крылов В. В., Смолярчук М. Я. и др. 188Rе-золедроновая кислота - новый отечественный радиофармпрепарат: первый клинический опыт // Поволжский онкол. Вестн. - 2014. -№ 3. -С. 41-46

Крылов B. В., Кочетова Т. Ю. Радионуклидная терапия 188Re-гидроксиэтилидендифосфонатом в лечении больных с метастазами в кости // Мед. радиол. и радиацион. безопасность. -2014. -№ 6. - С. 54 - 63.

Крылов В. В., Кочетова Т. Ю., Волознев Л. В. Радионуклидная терапия при метастазах в кости. Новые возможности // Вопр. онкол. - 2015. - Т. 61. -№ 1. - С. 14 - 19.

Петриев В. М., Сморызанова О. А., Скворцов В. Г. Изу чение фармакокинетики 188RЕ-КNА-гидроксиэтили дендифосфоната в организме интактных крыс // Вопр. биологич., мед. и фармацевт. химии. -2007. - № 2. -С. 11-16.

Aihara T, Kim Y, Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer // Ann Oncol. - 2002. - Vol. 13 (2). - P. 286-292.

Berthold DR, Pond GR, Soban F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study // J Clin Oncol. - 2008. - Vol. 10 (26). - P. 242-245.

Biersack HJ, Palmedo H, Andris A. et al. Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis // J Nucl Med. - 2011. - Vol. 52 (11). - P 1721-1726.

Body JJ. Metastatic bone disease: clinical and therapeutic aspects. Bone. 1992;13 Suppl 1:S57-62.

Chiang PH, Wang HC, Lai YL. et al. Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan // J Cancer Res Ther. - 2013. - Vol. 9 (4). - P. 653-659.

Chinnaiyan P, Huang S, Armstrong E, Harari PM. Radiosensitization following EGFR signaling inhibition by erlotinib (Tarceva) // Int J Radiat Oncol Biol Phys. - 2003. - Vol. 57 (2 Suppl). - S 294.

Cortes JE, Pazdur R. Docetaxel // J Clin Oncol. - 1995. - Vol. 13 (10). - P. 2643-2655.

Dafermou AF, Colamussi PF, Giganti M. F. et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer // Eur J Nucl Med. - 2001. - Vol. 28 (7). - P. 788-798.

de Bono JS, Logothetis CJ, Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer // N Engl J Med. - 2011. - Vol. 26 (364). - P. 1995-2005.

Enrique O, Zhonyun P, Prma EP et al. Efficacy and toxicity of Sm-153 EDTMP in the palliative treatment of painful bone metastases // World J Nucl Med. - 2002. - Vol. 1. - P 21-27.

Ernst DS, Tannock IF, Winquist EW. et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain // J Clin Oncol. - 2003. - Vol. 21 (17). - P. 3335-3342.

Esteva FJ, Valero V, Pusztai L. et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond // Oncologist. - 2001. - Vol. 6 (2). - P 133-146.

Fettich J, Padhy AK, Nair N, Morales R. Comparative clinical efficacy and safety of phosphorus and strontium-89 in the palliative treatment of metastatic bone apin: results of an IAEA coordination research project // W J Nucl Med. - 2003. - Vol. 2. - P 226-231.

Fizazi K, Yang J, Peleg S. et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survivalrelated genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts // Clin Cancer Res. -2003. - Vol. 9 (7). - P. 2587-2597.

Friedell HL, Storaasli JP The use of radioactive phosphorus in treatment of carcinoma of the breast with widespread metastasis in bone // AJR. - 1950. - Vol. 64. - P. 559575.

Graham C, Bond SS, Gerkovich MM, Cook MR. Use of the McGill pain questionnaire in the assessment of cancer pain: replicability and consistency // Pain. - 1980. - Vol. 8 (3). -0 P. 377-387.

Harari PM, Huang SM. Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development // Semin Radiat Oncol. - 2002. - Vol. 12 (3). - P. 21-26.

Haris JR, Hellmann S, Henderson IC. Breast disease. In: I H, editor. Chemotherapy Metastatic disease. 2nd: Lippincott Company, Philadelphia, PA, USA; 1991.

Hortobagyi GN, Gutterman JU, Blumenschein GR. et al. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG // Cancer. - 1979. - Vol. 44 (5). - P 1955-1962.

Kakonen SM, Selander KS, Chirgwin JM. et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways // J Biol Chem. - 2002. - Vol. 277 (27). - P. 24571-24578.

Knapp FF, Kropp J, Liepe K. Rhenium-188 generator-based radiopharmaceuticals for therapy. In: Baum RP, editor. Theraeutic Nulear Medicine. -Srpinger, Heidelberg -2014. -P 51-82.

Kraeber-Bodere F, Campion L, Rousseau C. et al. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement // Eur J Nucl Med. - 2000. - Vol. 27 (10). - P 1487-1493.

Krylov V., Kochetova T., Smolyarchuk M. et al. Evaluation of 188Re-KHEDP (Phosphoren) for palliative treatment in patients with bone metastases // World Journal of Nuclear Medicine. - 2013. -Vol. 12. -P. 255 - 256.

Lam MGH, Bosma TB, van Rijk PP, Zonneberg BA. 188Re-HEDP combined with capecitabine in hromon-refreactory prostate cancer patients with bone metastases: a phase I safety and toxicity study // Eur J Nucl Med Mol Imaging. - 2009. - Vol. 36. - P 1425-1433.

Lange R, de Klerk JM, Bloemendal HJ. et al. Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDP // Nucl Med Biol. - 2015. - Vol. 42 (5). - P. 465-469.

Li S, Liu J, Zhang H. et al. Rhenium-188 HEDP to treat painful bone metastases // Clin Nucl Med. - 2001. - Vol. 26 (11). - P 919-922.

Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases // Nucl Med Commun. - 2007. - Vol. 28. - P. 623-630.

Liepe K, Kotzerke J. Internal radiotherapy of painful bone metastases // Methods. - 2011. -Vol. 55 (3). - P. 258270.

Liepe K. Radium-223 chloride in bone pain treatment of prostate cancer // Nuklearmediziner. - 2015. - Vol. 38 (2). - P 131-137.

Liepe K, Runge R, Kotzerke J. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain // J Cancer Res Clin Oncol. - 2005. - Vol. 131 (1). - P. 60-66.

Liepe K, Runge R, Kotzerke J. Systemic radionuclide therapy in pain palliation // Am J Hosp Palliat Care. -2005. - Vol. 22 (6). - P. 457-464.

Liepe K, Geidel HH, Bergmann R. et al. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer // Nucl Med Commun. - 2009. - Vol. 30 (9). - P. 693-699.

Liepe K, Hliscs R, Kropp J. et al. Rhenium-188-HEDP in the palliative treatment of bone metastases // Cancer Biother Radiopharm. - 2000. - Vol. 15 (3). - P. 261-265.

Liepe K, Kropp J, Runge R, Kotzerke J. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases // Br J Cancer. - 2003. - Vol. 89 (4). - P. 625-629.

Liepe K, Franke WG, Kropp J. et al. Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases // Nuklearmedizin. - 2000. - Vol. 39 (6). - P. 146-151.

Liepe K, Hliscs R, Kropp J. et al. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases // J Nucl Med. - 2003. - Vol. 44 (6). - P. 953-960.

Liepe K, Geidel H, Haase M. et al. New model for the induction of osteoblastic bone metastases in rat // Anticancer Res. - 2005. - Vol. 25 (2A). - P. 1067-1073.

Lin A, Ray ME. Targeted and systemic radiotherapy in the treatment of bone metastasis // Cancer Metastasis Rev. - 2006. - 25 (4). - P. 669-675.

Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities // Nat Rev Cancer. - 2002. - Vol. 2 (8). - P. 584-593.

Nair N. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases // J Nucl Med. - 1999. - Vol. 40 (2). - P. 256-261.

Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy // J Clin Oncol. - 1991. - Vol. 9 (3). - P. 509-524.

Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer // J Urol. - 2002. - Vol. 168 (3). -P. 1005-1007.

O’Sullivan JM, Norman AR, McCready VR. et al. A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone // Eur J Nucl Med Mol Imaging. - 2006. - Vol. 33 (9). - P. 1055-1061.

Palmedo H, Guhlke S, Bender H et al. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases // Eur J Nucl Med. - 2000. - Vol. 27 (2). - P. 123-130.

Palmedo H, Manka-Waluch A, Albers P. et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate // J Clin Oncol. - 2003. - vol. 21 (15). - P. 2869-2875.

Paridaens R, Biganzoli L, Bruning P. et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over // J Clin Oncol. - 2000. - Vol. 18 (4). - P. 724-733.

Pecher P. Biological investigation with radioactive calcium and strontium. Preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer // University of California Publications in Pharmacology. -1942. - Vol. 2. - P. 117-149.

Pons F, Herranz R, Garcia A. et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer // Eur J NuclMed. - 1997. -Vol. 24 (10). - P. 1210-1214.

Porter AT, McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial // Semin Oncol. - 1993. - Vol. 20 (2). - P. 38-43.

Serafini AN. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease // Int J Radiat Oncol Biol Phys. - 1994. - Vol. 30 (5). - P. 1187-1194.

Shipman CM, Rogers MJ, Apperley J et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity // Br J Haematol. - 1997. - Vol. 98 (3). - P. 665-672.

Sledge GW, Neuberg D, Bernardo P. et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) // J Clin Oncol. - 2003. - Vol. 21 (4). - P. 588-592.

Smeland S, Erikstein B, Aas M. et al. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study // Int J Radiat Oncol Biol Phys. - 2003. - Vol. 56 (5).

Smolyarchuk M., Davydov G., Aleksandrova A. et al. Evaluation of the Pharmacokinetics of 188Re-HEDP and 99mTc-HDP in Humans // World Journal of Nuclear Medicine. - 2013. -Vol. 12. -P. 228 - 229.

Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine // J Nucl Med. - 1996. - Vol. 37 (3). - P. 538-546.

ter Heine R, Lange R, Breukels OB. et al. Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases // Int J Pharm. - 2014. - 25 (1). - P. 317-324.

Tu SM, Millikan RE, Mengistu B. et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial // Lancet. -2001. - Vol. 357 (9253). - P. 336-341.

von Moos R, Sternberg C, Body JJ, Bokemeyer C. Reducing the burden of bone metastases: current concepts and treatment options // Support Care Cancer. - 2013. - Vol. 24 (6). - P. 1773-1783.

Weinfurt KP, Anstrom KJ, Castel LD. Et al. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer // Ann Oncol. - 2006. - Vol. 17 (6). - P. 986-989.

World Health Organization. Cancer Pain Relief and Palliative Care: Report of a WHO Expert Committee. Geneva, Switzerland: World Health Organization. 1990.

Zhuikov BL. Production of medical radionuclides in Russia: Status and future-a review // Appl Radiat Isot. -2014. - Vol. 84. - P. 48-56.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...